

**In the Specification:**

Please amend the specification as shown:

Please delete paragraph [0010] and replace it with the following paragraph:

[0010] Various studies involving fibronectin (FN) and/or particular fibronectin peptides and wound healing have also been reported. Many of these studies involve the RGD sequence, part of the cell binding domain of FN (see Schor et al., J. Cell Science 109: 2581-2590 (1996); Steed et al., Diabetes Care 18(1): 39-46 (1995); Spousel et al., Am J. Physiology 267(2): F257-264 (1994); Kartha and Toback, J., Clinical Invest. 90(1): 288-292 (1992); Kishida et al., Biomaterials 13(13): 924-930 (1992)). Other portions of FN have also been studied for wound healing activity. U.S. Pat. No. 5,198,423 studied the effects of a polypeptide containing a cell binding domain and a heparin binding domain of FN on wound healing. U.S. Pat. No. 4,589,881 studied the effects of a 108 aa polypeptide fragment of FN on wound healing, as well as a biologically active fragment thereof. Sponsel et al. (1994) studied the effect of the tetrapeptide REDV (SEQ ID NO: 2) and the peptide LDVPS (SEQ ID NO: 3) on wound healing.